Dual-tracer PET/CT can ID those who need liver transplant

01/21/2013 | AuntMinnie.com (free registration)

PET/CT imaging using combined carbon-11 acetate and FDG performed better than contrast-enhanced CT in diagnosing hepatocellular carcinoma and staging tumors in liver transplant patients and in partial hepatectomy cases, according to a study in the Journal of Nuclear Medicine. The dual-tracer PET/CT method identified HCC lesions in 94% of liver transplant patients and in 96% of partial hepatectomy patients. In terms of tumor-nodal-metastasis staging, the dual method showed 91% accuracy for the liver transplant group and 90% for the partial hepatectomy group. Overall, the method demonstrated 97% sensitivity and 92% specificity for patient selection for liver transplantation. "The inclusion of dual-tracer PET/CT in pretransplant workup may warrant serious consideration" in improving the determination of patients who are the most in need of a liver transplant, the researchers said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY